Cardiovascular outcomes trial results for AstraZeneca PLC’s Onglyza (saxagliptin) and Takeda Pharmaceuticals USA Inc.’s Nesina (alogliptin) warrant new safety-related labeling for the diabetes drugs, but not distribution restrictions or market withdrawal, an FDA advisory committee said April 14.
In separate votes, FDA’s Endocrinologic and Metabolic Drugs Advisory Committee overwhelmingly recommended labeling changes for saxagliptin and alogliptin to reflect...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?